OR-OREGON-SYMPHONY
The Oregon Symphony is proud to announce that acclaimed Austrian-born conductor David Danzmayr will serve as its next Music Director with the launch of its 2021-2022 season and the symphony’s 125th anniversary year. Regarded as one of today’s most gifted conductors, Danzmayr recently served as Chief Conductor of the Zagreb Philharmonic Orchestra and Music Director of ProMusica Chamber Orchestra. He has conducted orchestras at some of the world's most prominent concert halls in Germany, Italy, Scotland and major cities across the United States. Danzmayr follows esteemed Music Director Carlos Kalmar , who has held the position with the Oregon Symphony for the last 18 years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210209005045/en/
“We are thrilled to have David joining the Oregon Symphony as a creative leader with a unique artistic vision,” shares Scott Showalter, Oregon Symphony President and CEO. “His inaugural season, with the implementation of his Creative Alliance, reflects his desire to embrace wide-ranging cultures while inspiring and challenging audiences, and is sure to open another rich chapter in Oregon Symphony history.”
Danzmayr holds a strong belief that a composer’s musical expression is shaped by their personal environment, family heritage and culture, which will be reflected in the Symphony’s 2021-2022 season programming and launch of the Oregon Symphony Creative Alliance. Danzmayr’s vision unites a wide-range of musical innovators to create vibrant work from unique perspectives. Under Danzmayr, the Creative Alliance will feature extraordinary artists and cultural thought leaders, including Nathalie Joachim, Gabriela Lena Frank, Jun Märkl, Gabriel Kahane, Simone Lamsma and Johannes Moser.
“The Oregon Symphony is one of the county's top orchestras, with talented musicians and a passionate community, and I am honored to have been selected as its next Music Director,” says Danzmayr.” As part of my agenda, I’m committed to building upon the Symphony's high standard of excellence with music that is meaningful to Oregon audiences.”
Danzmayr will join the four-time Grammy-nominated Oregon Symphony for its pivotal 125th anniversary, marking a profound milestone as the Symphony continues its legacy as the oldest orchestra in the Western United States.
"Oregon is proud to share 125 years with our beloved Oregon Symphony, and I want to personally welcome David Danzmayr as its new Music Director,” says Gov. Kate Brown. “The Oregon Symphony is one of our state’s artistic treasures, and the last 18 years with Carlos Kalmar as Music Director have been phenomenal. I can't wait to see what the symphony achieves under David’s leadership."
The Oregon Symphony will announce its 2021-2022 season in March 2021. For information about David Danzmayr, visit www.orsymphony.org/Danzmayr .
About Oregon Symphony
Led by Music Director Carlos Kalmar, the Oregon Symphony serves more than 235,000 people annually through concerts and award-winning education and community programs. The Symphony continues to innovate through series such as SoundSights, Sounds of Home and SoundStories. Follow the Oregon Symphony on Instagram and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005045/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom